10x Genomics Wins Patent Case Against Parse Biosciences

Regulation
โดย Zacks Investment Research·US·Read original
Summary · why it matters

10x Genomics secured a favorable jury verdict in its patent infringement case against Parse Biosciences, a Qiagen subsidiary, with the Delaware jury finding Parse willfully infringed three patents licensed to Scale Biosciences and awarding more than $4.8 million in damages. Despite the win, TXG shares slipped over 5% on Friday, though they remain up 277.4% year to date. The verdict reinforces 10x Genomics' intellectual property position in the single-cell analysis market, and the company plans to seek enhanced damages, attorneys' fees, and a permanent injunction in post-trial proceedings. The spatial biology market is projected to grow from $1.48 billion in 2026 to $7.24 billion by 2035, a CAGR of 19.2%, according to Custom Market Insights.

Impact on stocks 4

Biotech & Genomic Medicine± Mixed · 3 stocks
10X Genomics Inc
TXG
▲ PositiveRegulationrelevance

10x Genomics won a jury verdict confirming its patent rights against Parse Biosciences and plans to seek enhanced damages and an injunction.

Qiagen NV
QGEN
▼ NegativeRegulationrelevance

Qiagen subsidiary Parse Biosciences found to have willfully infringed 10x Genomics patents, exposing Qiagen to damages and a possible injunction.

Robotics & Physical AI▲ · 1 stocks

Off-coverage companies 2

Parse BiosciencesPrivate± Mixed
relevance

Scale BiosciencesPrivate± Mixed
relevance

© 2026 MarketDXNews